With the 2024 Community Oncology Conference, from the Community Oncology Alliance (COA), set to kick off this week in Orlando, Florida, The American Journal of Managed Care® spoke with Emily Touloukian, DO, COA board member and 1 of 6 cochairs for this year’s meeting, on highlights from the packed agenda and the power of advocacy.
The 2024 Community Oncology Conference, from the Community Oncology Alliance (COA), will take place April 3-5, in Orlando, Florida. Emily Touloukian, DO, medical oncologist, practice president, and managing partner at Coastal Cancer Center in Myrtle Beach, South Carolina, is 1 of this year's 6 meeting cochairs.
In this preview of the upcoming meeting, we discuss the power of advocacy and how the meeting is an invaluable resource for networking and learning from your peers in oncology.
Transcript
Why is the annual Community Oncology Conference is so important?
The volumes of knowledge housed in the minds of the COA membership is absolutely astounding, and getting to connect and network with other cancer care leaders from across the country, in my mind, is really one of the most important parts of the Community Oncology Conference. The agenda itself is packed with great topics, those that are integral to the day-to-day operations of the community oncology practice, as well as those covering new and innovative treatments and the unique ways they can be implemented in community oncology settings.
What excites you most about this year's meeting, as an attendee and a cochair?
For me, the number one thing that I enjoy at the Community Oncology [Conference] is networking with my colleagues: learning what is new and exciting in their practice, how they've implemented those things, and how they've handled challenges that have popped up. We really have a fantastic agenda, covering lots of great topics. I'm particularly looking forward to the AI [artificial intelligence] session and learning for what particular services it's being leveraged in practices, and how to implement those in my own practice. I think AI is coming into all of our lives, and seeing how we can utilize that to service different platforms to improve the patient experience is really exciting.
As moderator of the day 1 discussion, “Stronger Together: The Power of Advocacy to Support Patients & Practices,” can you tell us what this panel will address?
Absolutely. You know, advocacy is really the cornerstone of COA, and the aim of our panel is to demystify advocacy, discuss the many different forms it can take and how to really be an effective advocate. We have a fantastic group of panelists with really diverse backgrounds, and my hope is that everyone in attendance will walk away from the session with an idea of either how they can start to be an advocate or improve or add to their current advocacy efforts.
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Congress Urged to Repeal Comstock Act Threatening Reproductive Rights and Public Health
May 16th 2024In a joint letter addressed to Congress, Healthcare Across Borders, Take Back the Court Action Fund, and UltraViolet Action called out the resurgence of the Comstock Act, urging immediate action to repeal this century-old law that threatens reproductive rights and public health in the US.
Read More
Atypical Marker Expression in T-Cell Acute Lymphoblastic Leukemia/Lymphoma
May 15th 2024Two unique case reports highlight the diagnostic challenges and critical importance of comprehensive immunophenotyping in cases of T-cell acute lymphoblastic leukemia/lymphoma that present without typical immaturity markers but with rare γδ T-cell receptor expression.
Read More